Clear all da

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510



05 JUL 28

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name	,			
Mr.	Marc B.	Samuels		
2. Address Che	ck if different than previously reported	<u> </u>	<u></u>	
823 Congress		Suite 900		
Austin		TX 78701	US	
3. Principal place of business (if	different than line 2)			
City	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	State/Zip or Country		
4a. Contact Name	b. Telephone number	c. E-mail	5. Senate ID#	
Ms. Linda Lucko	512/480-8962	llucko@hillcopartners.com		
7. Client Name Self IDEC Pharmaceuticals			6. House ID # 35506013	
10. Check if this is a Termination  INCOME OR EXPENS	ES - Complete Either L		11. No Lobbying Activ	
12. Lobbying Firms		13. Organizations		
INCOME relating to lobbying activities for this reporting period was:		EXPENSES relating to lobbying were:	<b>EXPENSES</b> relating to lobbying activities for this reporting were:	
Less than \$10,000		Less than \$10,000		
\$10,000 or more 🗵 😝 🖠	40,000	\$10,000 or more	\$	
Provide a good faith estimate, of all lobbying related income		14. REPORTING METHOD. accounting method. See instruc		
payments to the registrant by a activities on behalf of the clien	my other entity for lobbying		mounts using LDA definitions on mounts under section 6033(b)(8)	
			mounts under section 162(e) of the	
			Edit >	
Signature		Date	3K-05	
Printed Name and Title Ma	arc B. Samuels		•	

Registrant Name Marc B. Samuels	Client Name IDEC Pharmaceuticals	
LOBBYING ACTIVITY. Select as many codes as ne engaged in lobbying on behalf of the client during the re information as requested. Attach additional page(s) as a	porting period. Using a separate page for each code	
15. General issue area code MMM - Medicare/Medicaid	(one per page)	
16. Specific lobbying issues		
Work related to coverage and payment for zevalin; inc	cluding coverage of off-label indications	
17. House(s) of Congress and Federal agencies contacted	ed Check if None	
Centers for Medicare and Medicaid Services Federal Food and Drug Administration		
18. Name of each individual who acted as a lobbyist in	this issue area	
Name	Covered Official Position (if applicable)	
Marc B. Samuels		
	······································	
19. Interest of each foreign entity in the specific issues	listed on line 16 above \( \overline{\overline	
Signature	Date 2/15) 15	

Filing #00c77543-baaf-4ce1-b888-c2b518ac442d - Page 3 of 4

LD-2DS (REV. 4/03)

Page 2